Top Healthcare Stocks by UQS Score

1132 stocks scored · Last updated May 24, 2026

Healthcare is one of the few sectors where demand is structurally guaranteed — aging populations, chronic disease prevalence, and innovation-driven treatment cycles create persistent tailwinds regardless of economic conditions. But the sector spans an enormous range: from cash-burning biotech startups hoping for FDA approval to diversified pharma giants with decades of patent-protected revenue. The UQS model cuts through this noise by scoring actual financial performance and balance sheet health, not pipeline potential. Companies ranked highest here have already demonstrated they can turn scientific innovation into profitable, sustainable businesses.

Healthcare Sector Characteristics

Healthcare encompasses pharmaceuticals, biotechnology, medical devices, managed care, hospital systems, and life science tools. What makes the sector unique for scoring is its bimodal distribution: large pharma companies tend to have exceptional quality scores (high margins from patented drugs) but modest growth scores (patent cliffs create revenue headwinds), while smaller biotech companies show the inverse pattern. Medical device companies often hit a sweet spot — consistent revenue growth with defensible market positions and recurring consumable revenue. The UQS model captures these dynamics by scoring each metric independently, so a pharma company isn't penalized for slow growth if it excels everywhere else.

Scoring note: Healthcare uses consumer-sector thresholds (25% ROIC, 30% operating margin) because pharmaceutical margins vary widely depending on patent cliffs and R&D spending cycles. Biotech companies with negative earnings can still score well on growth and moat if they have strong pipelines and low debt.

Healthcare Sector Score Overview

70

Avg UQS Score

85

Avg Quality

46

Avg Moat

71

Avg Growth

85

Avg Risk

74

Avg Valuation

Top Healthcare Stocks: Who Leads and Why

#1HALOHalozyme Therapeutics, Inc.78

Halozyme Therapeutics, Inc. leads healthcare with a 78 UQS score, driven by a 99 quality rating that reflects superior margins and capital returns. Its moat score of 63 confirms deep competitive advantages in its therapeutic areas.

#2INCYIncyte Corporation78

Incyte Corporation scores 78 overall, balancing strong profitability (quality: 94) with a robust balance sheet (risk: 100). A well-diversified revenue base supports scoring consistency.

#3CPRXCatalyst Pharmaceuticals, Inc.76

At 76, Catalyst Pharmaceuticals, Inc. earns the third spot with notable strength in valuation (80) — suggesting the market may be underpricing its fundamentals relative to the quality of the business.

#4RMDResMed Inc.74

ResMed Inc. scores 74 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

#5ARGXargenx SE72

argenx SE scores 72 with balanced pillar scores, indicating a well-rounded healthcare business with no major scoring weaknesses.

Full Healthcare Ranking: Top 25 Stocks

#	Stock	UQS	Q	M	G	R	V
1	HALOHalozyme Therapeutics, Inc.	78	99	63	83	49	91
2	INCYIncyte Corporation	78	94	44	75	100	91
3	CPRXCatalyst Pharmaceuticals, Inc.	76	91	42	79	100	80
4	RMDResMed Inc.	74	90	52	62	100	71
5	ARGXargenx SE	72	70	55	100	100	39
6	VRTXVertex Pharmaceuticals Incorporated	70	84	55	63	100	53
7	AUPHAurinia Pharmaceuticals Inc.	70	93	41	71	91	72
8	RIGLRigel Pharmaceuticals, Inc.	70	100	35	61	88	100
9	ADMAADMA Biologics, Inc.	70	95	46	77	87	68
10	CRMDCorMedix Inc.	70	97	46	54	83	75
11	NUTXNutex Health, Inc.	70	93	32	69	76	100
12	HRMYHarmony Biosciences Holdings, Inc.	70	78	43	79	98	99
13	CGENCompugen Ltd.	70	99	25	63	100	98
14	LLYEli Lilly and Company	70	86	58	100	53	38
15	EXELExelixis, Inc.	70	99	41	53	82	78
16	ANIPANI Pharmaceuticals, Inc.	69	62	32	100	74	95
17	DXCMDexCom, Inc.	69	84	50	76	79	55
18	NBIXNeurocrine Biosciences, Inc.	69	82	38	90	73	65
19	UTHRUnited Therapeutics Corporation	68	83	53	48	100	66
20	DOCSDoximity, Inc.	67	87	58	40	82	73
21	GLPGGalapagos N.V.	67	66	33	63	100	100
22	ALNYAlnylam Pharmaceuticals, Inc.	67	71	53	100	72	36
23	REGNRegeneron Pharmaceuticals, Inc.	66	71	46	48	100	84
24	ISRGIntuitive Surgical, Inc.	66	73	58	81	82	31
25	GSKGSK plc	66	83	59	52	43	90

Filter all 1132+ healthcare stocks in the full directory

Browse All Stocks

Frequently Asked Questions About Healthcare Stocks

How does UQS handle biotech companies with no revenue?

Pre-revenue biotech companies typically score low overall because most UQS metrics require financial data (revenue, margins, earnings). Their quality score will be near zero, and growth metrics that depend on trailing revenue won't have data. However, if a biotech has low debt and strong cash reserves, it can score reasonably on risk. The moat score, being AI-driven, can also recognize strong IP portfolios and regulatory moats even for pre-revenue companies.

Why do healthcare stocks often score high on quality?

Pharmaceutical companies with patent-protected drugs enjoy some of the highest margins in the market — gross margins of 70-80% are common. Patents create temporary monopolies that allow premium pricing, and the regulatory approval process creates enormous barriers to entry. These structural advantages directly translate into high ROIC, wide operating margins, and strong free cash flow generation — exactly what the quality pillar measures.

What impact do patent cliffs have on UQS scores?

Patent expiration directly affects growth scores as revenue from blockbuster drugs declines. Quality scores may also dip as margins compress from generic competition. However, well-managed pharma companies with diversified pipelines often maintain their overall UQS scores by replacing expiring revenue with new drug launches. The three-year revenue CAGR in the growth pillar helps distinguish between transient patent cliff effects and structural decline.